NCT00829205View on ClinicalTrials.gov

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2009

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

DIETARY_SUPPLEMENT

Se-methyl-seleno-L-cysteine

DRUG

carboplatin

DRUG

etoposide

DRUG

ifosfamide

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (5)

EC1A 7BE

Barts and the London NHS Trust, London

Saint Bartholomew's Hospital, London

M20 4BX

Christie Hospital, Manchester

PL6 8DH

Derriford Hospital, Plymouth

SO16 6YD

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER

NCT00829205 - Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | Biotech Hunter | Biotech Hunter